H. Lundbeck Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Charl van Zyl

Chief Executive Officer (CEO)

kr.39.6m

Compensación total

Porcentaje del salario del CEO	6.8%
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	1.8yrs
Promedio de permanencia en la Junta Directiva	3.2yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Charl van Zyl en comparación con los beneficios de H. Lundbeck?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	kr.40m	kr.3m	kr.2b

Compensación vs. Mercado: La compensación total de Charl($USD5.65M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD2.61M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Charl con los resultados de la empresa.

CEO

Charl van Zyl (56 yo)

less than a year

Permanencia

kr.39,600,000

Compensación

Mr. Charl van Zyl served as Executive Vice President Neurology Solutions & Head of EU/International at UCB SA since February 2020 until June 2023. He serves as President and Chief Executive Officer of H. L...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Charl van Zyl	President & CEO	less than a year	kr.39.60m	sin datos
Joerg Hornstein	CFO & Executive VP of Corporate Functions	1.8yrs	kr.10.90m	0.0023% DKK 733.5k
Lars Bang	Executive Vice President of Product Development & Supply	5.3yrs	kr.10.10m	0.038% DKK 12.4m
Per Luthman	Executive Vice President of Research & Development	5.3yrs	kr.11.30m	0.014% DKK 4.5m
Tarek Samad	Senior VP & Head of Research	3yrs	sin datos	sin datos
Palle Olesen	Chief Specialist & VP of Investor Relations	no data	sin datos	sin datos
Tine Hansen	Senior Vice President of Corporate Communications & Public Affairs	less than a year	sin datos	sin datos
Dianne Holto	Executive Vice President of People & Organization	less than a year	sin datos	sin datos
Ole Chrintz	Senior Vice President of International Markets	no data	sin datos	sin datos
Rupert Sandbrink	Senior VP & Head of Clinical Development	2.3yrs	sin datos	sin datos
Bjorn Mogensen	Senior Vice President of Group Finance	1.8yrs	sin datos	sin datos
Jose Molinuevo	VP & Head of Experimental Medicine	no data	sin datos	sin datos

1.8yrs

Permanencia media

57.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de HLUNBC no se considera experimentado ( 1.7 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Lars Rasmussen	Independent Chairman	11.3yrs	kr.1.70m	0.010% DKK 3.3m
Lene Skole-Sorensen	Deputy Chairman	9.3yrs	kr.1.20m	0.0062% DKK 2.0m
Jeffrey Berkowitz	Independent Director	6.2yrs	kr.1.20m	sin datos
Lars Holmqvist	Director	9.3yrs	kr.600.00k	0.0076% DKK 2.4m
Jakob Riis	Director	1.2yrs	kr.450.00k	0.0055% DKK 1.8m
Ilse Wenzel	Independent Director	3.2yrs	kr.70.00k	sin datos
Santiago Arroyo	Independent Director	3.2yrs	kr.1.00m	sin datos
Camilla Andersson	Employee Representative Director	2.2yrs	kr.400.00k	0.00010% DKK 32.3k
Dorte Clausen	Employee Representative Director	2.2yrs	kr.400.00k	0.00011% DKK 35.5k
Hossein Armandi	Employee Representative Director	2.2yrs	kr.400.00k	sin datos
Lasse Skibsbye	Employee Representative Director	2.2yrs	kr.400.00k	sin datos

3.2yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de HLUNBC se considera experimentada (3.1 años de antigüedad promedio).

H. Lundbeck Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

Recent updates

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Less than half of directors are independent

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad